Treatment of liver cirrhosis using hepatocyte-derived liver progenitor-like cells: a prospective, open-label, single-arm, safety trial.

Additionally, in patients with compensated cirrhosis (MELD 10–17), autologous monocyte-derived macrophages demonstrated a favorable safety profile and clinical promising trends, including a reduction in MELD scores at day 90, a lower incidence of liver-related SAEs, and favorable anti-inflammatory cytokine changes, though the primary endpoint narrowly missed statistical significance (ΔΔMELD –0.87, p = 0.06).

also in 86 other papers

Although changes in serum ALT and AST levels did not reach statistical significance, likely due to the mild elevation of these enzymes in the TAA model as well as the limited persistence of human HepLPCs in rat models (Fig. 3a ), the trends suggest a potential ameliorating effect of HepLPCs on liver damage.

also in 39,124 other papers